Rezolute, Inc. (RZLT)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$4.58+0.88%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · RZLT
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -42.8% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 399 industry peers
RZLT — earnings miss
Dated 2026-02-12
Results of Operations and Financial Condition. On February 12, 2026, Rezolute, Inc. issued a press release announcing its financial results for the second quarter ended December 31, 2025. A copy of this press release is attached hereto as Exhibit 99.1. The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of…
Why it matters: R&D spending is a key driver of growth. Changes could indicate shifts in strategy or financial health.
Watch forR&D spending as a percentage of sales increases beyond 24%.
Also watch forR&D spending as a percentage of sales decreases below 24%.
Why it matters: If the health care sector grows faster, it could help Rezolute's performance. This is important as the sector is slowing down.
Supportive ifHealth care sector revenue growth returns to above 10% year over year.
Worry ifHealth care sector revenue growth stays below 5% year over year.
Why it matters: A drop in revenue growth could signal a slowdown in the overall healthcare sector.
Worry ifRezolute's revenue growth falls below the median growth rate of 5% for the healthcare sector.
Less concerning ifRevenue growth remains above the median growth rate of 5% for the healthcare sector.
Why it matters: Earnings results will show if the positive trend continues after the recent earnings beat.
Supportive ifQ4 earnings per share beats analyst expectations by more than 10%.
Worry ifQ4 earnings per share falls short of analyst expectations by more than 10%.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$194 on $10,000 · ±1.9% | How much price usually moves either way. |
| Bad day | $785 loss on $10,000 · 7.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,720 loss on $10,000 · 87.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Lower R&D costs show better money management. This is important for a company that is losing money.
Supportive ifR&D expenses decrease further from $11.4 million in Q3 2026.
Worry ifR&D expenses increase or remain flat compared to the previous quarter.
Why it matters: A drop in revenue growth could signal a slowdown in the company's performance. This could impact future earnings.
Worry ifRevenue growth falls below the median for the sector, which is currently around 24%.
Less concerning ifRevenue growth remains above the median for the sector.
Why it matters: Top results will show if ersodetug helps with tumor hyperinsulinism. This could change future approvals.
Supportive ifTopline results show that at least 50% of participants reached the main goal.
Worry ifTopline results show that less than 50% of participants reached the main goal.
Why it matters: FDA's response will show if Rezolute can move forward with ersodetug for congenital HI. Positive feedback may help it get approved.
Supportive ifFDA agrees to move forward with the congenital HI program based on the data given.
Worry ifFDA does not move forward with the congenital HI program or asks for more studies.
Why it matters: The FDA's response will shape the approval process for ersodetug. Good feedback could speed up approval.
Supportive ifThe FDA shows support for sending complete data for review.
Worry ifThe FDA has worries that slow down the development of ersodetug.
Why it matters: Topline results will show how well ersodetug works for tumor hyperinsulinism. This is key for future approval.
Supportive ifTop results show that at least 50% of participants lower their IV glucose needs.
Worry ifTopline results show less than 50% of participants meet the primary endpoint.
Why it matters: Completing enrollment is crucial for timely topline results. It shows the study is on track.
Supportive ifAll 16 participants are enrolled in the upLIFT study.
Worry ifEnrollment does not complete as planned, delaying topline results.